Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

- FDA Meeting Expected in Q4 2019 and BLA Submission for PRV-031 (teplizumab) Targeted for Q4 2020 - Total Net Proceeds of $62.7 million from Recent Offerings, Together with Current Cash Position, Expected to Fund Operations for Two Years -

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here